RELAPSING MULTIPLE SCLEROSIS

This study tests an experimental drug called obexelimab in 93 adults with relapsing multiple sclerosis. The goal is to see if it reduces new brain lesions and is safe. Participants receive either the drug or a placebo, and neither they nor their doctors know which one they get.

This study tests whether a shot under the skin (subcutaneous) of the drug ublituximab works as well as the standard IV infusion for people with relapsing multiple sclerosis. About 360 adults with MS will be randomly assigned to one of the two methods. The main goal is to compare …

This study looks at whether a year of treatment with Ocrevus can improve walking and balance in people with relapsing multiple sclerosis, compared to other standard medications. Sixty adults aged 18-65 who can walk at least 25 feet will be split into two groups and followed for o…

This study watches 106 people with relapsing multiple sclerosis in Austria to see if starting the drug Ofatumumab (Kesimpta) earlier makes a difference compared to starting it later. Over 2 years, researchers track how well the drug controls relapses, brain lesions, and disabilit…

This study checks the long-term safety of the drug tolebrutinib in about 2,500 adults with multiple sclerosis who were in earlier trials. Participants take the drug for up to several years while doctors watch for side effects and track disability. The goal is to see if the drug r…

This phase 3 study tests whether remibrutinib, a new daily pill, works better than teriflunomide at reducing multiple sclerosis relapses and slowing disability. About 1,000 adults with relapsing MS will take one of the two drugs for a year or more. The goal is to see if remibruti…

This study tests whether a new drug called remibrutinib works better than an existing medication, teriflunomide, for people with relapsing multiple sclerosis (RMS). About 1,000 adults aged 18 to 55 with RMS are taking part. The main goal is to see if remibrutinib reduces the numb…

This study compares a new oral drug, fenebrutinib, with an approved medication, teriflunomide, in about 750 adults with relapsing multiple sclerosis (MS). The goal is to see if fenebrutinib better reduces relapses and slows disability progression. Participants take one of the two…

This study tests whether a new drug, fenebrutinib, is better than an existing medication (teriflunomide) at reducing relapses and slowing disability in people with relapsing multiple sclerosis. About 746 adults with MS will be randomly assigned to one of the two treatments. The m…

This study follows about 1,800 people with relapsing multiple sclerosis who have already taken ofatumumab in a previous Novartis trial. Researchers want to see how safe and effective the drug is over the long term, including its effects on vaccines and COVID-19 immunity. Particip…

This study tests whether fenebrutinib can reduce brain lesions in people with relapsing multiple sclerosis (RMS). About 109 participants received either the drug or a placebo, and brain scans were taken over 12 weeks. The goal is to see if fenebrutinib slows disease activity, wit…

This study looks at how the drug ocrelizumab changes certain markers in the spinal fluid of people newly diagnosed with relapsing multiple sclerosis (MS) or a high-risk first episode. The goal is to see if early treatment can reduce signs of chronic inflammation in the brain. Abo…